María Ciria Calduch

Title: Inventor María Ciria Calduch: Innovating Cancer Treatment

Introduction

María Ciria Calduch is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of cancer treatment through his innovative research and inventions. His work focuses on predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy.

Latest Patents

María Ciria Calduch holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity in cancer patients based on the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also identifies this set of miRNAs as a biomarker for predicting cardiotoxicity risk in patients receiving anthracyclines chemotherapy. Furthermore, it contemplates a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.

Career Highlights

Throughout his career, María Ciria Calduch has worked with esteemed institutions such as Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. His research has been pivotal in advancing the understanding of cardiotoxicity in cancer treatments.

Collaborations

He has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. Their joint efforts have contributed to the development of innovative solutions in the medical field.

Conclusion

María Ciria Calduch's work exemplifies the intersection of innovation and healthcare, particularly in improving the safety of cancer treatments. His contributions are vital for enhancing patient outcomes and advancing medical research.